Suboptimal immunity of hepatitis B vaccination and seroprotection among healthcare professionals in a tertiary hospital in Ghana. [PDF]
Antuamwine BB +3 more
europepmc +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Impact of Distributing Test Result Reports for Chronic Viral Hepatitis on Awareness of Hepatitis Testing Among Non-Specialist Physicians. [PDF]
Itakura J +8 more
europepmc +1 more source
Psychoactive prescription drug use and misuse in patients on opioid agonist treatment
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro +5 more
wiley +1 more source
Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis. [PDF]
Abo Zeid M +10 more
europepmc +1 more source
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin +6 more
wiley +1 more source
A Decade of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention's Epidemiologic and Economic Modeling Agreement. [PDF]
Abimbola TO +10 more
europepmc +1 more source
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon +12 more
wiley +1 more source
Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study. [PDF]
Jeong O +7 more
europepmc +1 more source

